Khanna, Sahil

The epidemiology of community-acquired Clostridium difficile infection: a population-based study

Khanna, S., Pardi, D. S., Aronson, S. L., Kammer, P. P., Orenstein, R., St Sauver, J. L., Harmsen, S. W., & Zinsmeister, A. R. (2012) · American Journal of Gastroenterology

Clostridium difficile and Clostridium perfringens researchInfection Control in Healthcare

Cited by 622

Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clostridioides difficile Infection

Khanna, S., Assi, M., Lee, C., Yoho, D., Louie, T., Knapple, W., Aguilar, H., Garcia-Diaz, J., Wang, G. P., Berry, S. M., et al. (2022) · Drugs

Clostridium difficile and Clostridium perfringens researchGut microbiota and health

Cited by 301

2019 update of the WSES guidelines for management of Clostridioides (Clostridium) difficile infection in surgical patients

Sartelli, M., Di Bella, S., McFarland, L. V., Khanna, S., Furuya-Kanamori, L., Abuzeid, N., Abu-Zidan, F. M., Ansaloni, L., Augustin, G., Bala, M., et al. (2019) · World Journal of Emergency Surgery

Clostridium difficile and Clostridium perfringens researchSurgical site infection prevention

Cited by 159

Results from a randomized placebo-controlled clinical trial of a RBX2660-a microbiota-based drug for the prevention of recurrent Clostridium difficile infection

Dubberke, E. R., Lee, C. H., Orenstein, R., Khanna, S., Hecht, G., & Gerding, D. N. (2018) · Clinical Infectious Diseases

Clostridium difficile and Clostridium perfringens researchGut microbiota and health

Cited by 140

Effect of Ursodeoxycholic Acid Use on the Risk of Colorectal Neoplasia in Patients with Primary Sclerosing Cholangitis and Inflammatory Bowel Disease: A Systematic Review and Meta-analysis

Singh, S., Khanna, S., Pardi, D. S., Loftus, E. V., & Talwalkar, J. A. (2013) · Inflammatory Bowel Diseases

Liver Diseases and ImmunityInflammatory Bowel Disease

Cited by 94

Safety and Tolerability of SER-109 as an Investigational Microbiome Therapeutic in Adults With Recurrent Clostridioides difficile Infection: A Phase 3, Open-Label, Single-Arm Trial

Sims, M. D., Khanna, S., Feuerstadt, P., Louie, T. J., Kelly, C. R., Huang, E. S., Hohmann, E. L., Wang, E. E. L., Oneto, C., Cohen, S. H., et al. (2023) · JAMA Network Open

Clostridium difficile and Clostridium perfringens researchGut microbiota and health

Cited by 83